+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro and in vivo studies of targeted alpha therapy for melanoma, leukaemia, breast, prostate, and colorectal cancer



In vitro and in vivo studies of targeted alpha therapy for melanoma, leukaemia, breast, prostate, and colorectal cancer



Proceedings of the American Association for Cancer Research Annual Meeting 42: 94




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035105523

Download citation: RISBibTeXText


Related references

In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers. Critical Reviews in Oncology/Hematology 39(1-2): 139-146, 2001

In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer. Colorectal Disease 3(5): 345-353, 2001

Anti-ERBb4 targeted therapy combined with radiation therapy in prostate cancer. Results of in vitro and in vivo studies. Cancer Biology and Therapy 7(7): 1090-1094, 2008

Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. Critical Reviews in Oncology/Hematology 123: 7, 2018

Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. Critical Reviews in Oncology/Hematology 123: 7-20, 2018

Targeted radiotherapy and gene therapy for prostate cancer Transfection of the noradrenaline transporter gene under the control of telomerase promoters; in vitro and in vivo studies. European Urology Suppl.s 3(2): 93, 2004

New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations. Investigational new Drugs 36(6): 985-998, 2018

In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595. Cancer Biology and Therapy 4(8): 848-853, 2005

Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. International Journal of Radiation Oncology, Biology, Physics 60(3): 896-908, 2004

Apoptosis-targeted prostate cancer drug development Synthesis of a novel class of cyclic hydroxamic acid with potent anti-prostate cancer effect in vitro and in vivo. Journal of Urology 159(5 Suppl. ): 132, 1998

Antipeptidergic therapy of prostate cancer In vitro and in vivo studies. Jonat, W , Kaufmann, M , Munk, K Contributions to Oncology; Hormone-dependent tumors: Basic research and clinical studies 324-331, 1995

In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells. Prostate 68(8): 849-860, 2008

Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma. Oncotarget 8(34): 56311-56326, 2017

Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo. Drug Delivery 23(5): 1757-1762, 2016

Gene therapy of advanced prostate cancer by in vivo transduction with prostate-targeted antisense c-myc RNA retroviruses. Proceedings of the American Association for Cancer Research Annual Meeting 37: 344, 1996